Public Sector Pension Investment Board Has $34.47 Million Stock Holdings in Elevance Health, Inc. $ELV

Public Sector Pension Investment Board boosted its position in shares of Elevance Health, Inc. (NYSE:ELV) by 515.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 106,682 shares of the company’s stock after acquiring an additional 89,350 shares during the period. Public Sector Pension Investment Board’s holdings in Elevance Health were worth $34,471,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of ELV. Physician Wealth Advisors Inc. increased its position in shares of Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after purchasing an additional 63 shares during the period. Activest Wealth Management boosted its stake in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its holdings in Elevance Health by 94.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after buying an additional 37 shares during the period. BOK Financial Private Wealth Inc. bought a new stake in Elevance Health in the 2nd quarter valued at $32,000. Finally, Motco raised its stake in shares of Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after buying an additional 77 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Key Headlines Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: MSN published a bullish take highlighting two reasons to like ELV (and one caution). The piece frames the company’s recent operational strength and valuation as positives that support the stock’s move higher. 2 reasons to like ELV (and 1 not so much)
• Positive Sentiment: Recent reported results: ELV beat Q3/Q4 consensus on EPS ($3.33 vs. $3.10) and posted ~9.6% revenue growth year-over-year; management set FY2026 EPS guidance around $25.50 — these items underpin investor confidence in near-term profitability and support valuation (PE ~13.4).
• Neutral Sentiment: Zacks issued a mixture of tweaks to quarterly models — it raised a few near‑term quarter estimates (e.g., Q4 2027 and Q3 2027 uplift) while leaving a “Hold” rating in place. Those isolated raises offer limited upside until broader guidance/trajectory is confirmed.
• Negative Sentiment: Zacks materially trimmed several near‑term and full‑year forecasts: FY2026 down to ~$25.53 (from ~$29.01) and FY2027 to ~$28.40 (from ~$31.89), plus multiple Q1/Q2 quarter cuts. The cuts reduce forward EPS expectations and could weigh on the stock if other analysts follow suit or if management doesn’t reaffirm stronger guidance.

Elevance Health Stock Performance

NYSE ELV opened at $336.24 on Friday. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company has a 50 day moving average of $351.89 and a 200-day moving average of $331.31. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70. The firm has a market cap of $74.21 billion, a price-to-earnings ratio of 13.39, a PEG ratio of 1.84 and a beta of 0.50.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. During the same period in the prior year, the company earned $3.84 EPS. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ELV shares. UBS Group set a $400.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Robert W. Baird raised their price target on shares of Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Guggenheim decreased their price objective on Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Zacks Research raised Elevance Health from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. Finally, Leerink Partners raised their target price on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a research report on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health presently has an average rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.